BRPI0512584A - método para prevenir ou tratar infecções respiratórias e otite média em lactentes - Google Patents

método para prevenir ou tratar infecções respiratórias e otite média em lactentes

Info

Publication number
BRPI0512584A
BRPI0512584A BRPI0512584-7A BRPI0512584A BRPI0512584A BR PI0512584 A BRPI0512584 A BR PI0512584A BR PI0512584 A BRPI0512584 A BR PI0512584A BR PI0512584 A BRPI0512584 A BR PI0512584A
Authority
BR
Brazil
Prior art keywords
respiratory infections
infants
otitis media
prevent
treat respiratory
Prior art date
Application number
BRPI0512584-7A
Other languages
English (en)
Inventor
Erika Isoulauri
Seppo Salminen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0512584A publication Critical patent/BRPI0512584A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODO PARA PREVENIR OU TRATAR INFECçõES RESPIRATóRIAS E OTITE MéDIA EM LACTENTES A presente invenção refere-se a um método inovador para prevenir ou tratar inecções respiratórias em otite média aguda em lactentes, O método compreende a administração de uma quantidade terapeuticamente eficaz de uma cepa de bididobactéria e um probiótico promotor de aderência, tal como LGG, ao lactente.
BRPI0512584-7A 2004-07-01 2005-07-01 método para prevenir ou tratar infecções respiratórias e otite média em lactentes BRPI0512584A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58483004P 2004-07-01 2004-07-01
PCT/US2005/023330 WO2006007526A1 (en) 2004-07-01 2005-07-01 Method for preventing or treating respiratory infections and acute otitis media in infants

Publications (1)

Publication Number Publication Date
BRPI0512584A true BRPI0512584A (pt) 2008-03-25

Family

ID=35058735

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512584-7A BRPI0512584A (pt) 2004-07-01 2005-07-01 método para prevenir ou tratar infecções respiratórias e otite média em lactentes

Country Status (13)

Country Link
US (1) US7862808B2 (pt)
EP (1) EP1768681A1 (pt)
KR (1) KR20070052246A (pt)
CN (1) CN101014351B (pt)
BR (1) BRPI0512584A (pt)
CA (1) CA2570481C (pt)
HK (1) HK1111883A1 (pt)
MX (1) MXPA06014555A (pt)
MY (1) MY145410A (pt)
NO (1) NO341408B1 (pt)
RU (1) RU2332224C1 (pt)
TW (1) TWI374745B (pt)
WO (1) WO2006007526A1 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ATE361101T1 (de) * 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
WO2007144334A1 (en) * 2006-06-13 2007-12-21 Nestec S.A. Prevention and treatment of otitis media with non-pathogenic bacterial strains
EP2068899B1 (en) 2006-10-02 2015-07-01 DuPont Nutrition Biosciences ApS Lactobacillus acidophilus for use in reducing the incidence and duration of respiratory infections
DK1992351T3 (en) * 2007-05-18 2016-06-06 Nestec Sa Lactobacillus johnsonii for the prevention of post-surgical infection
WO2009021585A1 (en) * 2007-08-13 2009-02-19 Dsm Ip Assets B.V. Probiotic bacteria for rducing the occurence of symptoms of winter infections
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
CA2719719A1 (en) * 2008-03-28 2009-10-01 Nestec S.A. Probiotics for use in expecting female mammals for enhancing the immunity of their offsprings
WO2009151315A1 (en) * 2008-06-13 2009-12-17 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
AR072142A1 (es) 2008-06-13 2010-08-11 Nutricia Nv Nutricion para prevenir infecciones.proceso. composicion. uso.
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
AU2010277582A1 (en) * 2009-07-31 2012-02-02 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
EP2335502A1 (en) * 2009-12-07 2011-06-22 Nestec S.A. An infant formula delivery system comprising probiotics and an infant nutritional formulation
WO2011093907A1 (en) * 2010-02-01 2011-08-04 Corn Products International, Inc. High-purity galactooligosaccharides and uses thereof
CN103220921B (zh) * 2010-10-15 2015-12-16 科.汉森有限公司 免疫佐剂
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2452571A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of complementary infant/young child nutritional compositions
EP2452575A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of age-tailored nutritional formula with probiotics
US20120128644A1 (en) * 2010-11-24 2012-05-24 Oragenics, Inc. Use of Bacteria to Treat and Prevent Respiratory Infections
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10039296B2 (en) 2011-06-20 2018-08-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
EP2802333B1 (en) * 2012-01-13 2020-03-11 Chr. Hansen A/S Lactobacillus rhamnosus and bifidobacterium animalis subsp. lactis for use in prevention or treatment of upper respiratory tract infections
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
WO2013187755A1 (en) 2012-06-14 2013-12-19 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
WO2014178007A2 (en) * 2013-05-02 2014-11-06 Pinaki Panigrahi A pharmaceutical composition comprising a combination of probiotic and prebiotic
PL2994150T3 (pl) 2013-05-10 2019-09-30 H.J. Heinz Company Brands Llc Probiotyki i sposoby zastosowania
EP3111942B1 (en) 2013-11-15 2021-01-06 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
WO2015140299A1 (en) 2014-03-20 2015-09-24 Universiteit Antwerpen Oronasopharyngeal probiotics
FI127483B (en) * 2014-06-11 2018-07-13 Gut Guide Oy Microbial marker for celiac disease and related product
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2018217764A1 (en) * 2017-05-22 2018-11-29 Kansas State University Research Foundation Microbiome transplantation
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
ES2898876T3 (es) 2018-01-26 2022-03-09 Probisearch S L U Composición que comprende una nueva cepa de Lactobacillus salivarius y método para la prevención y el tratamiento de otitis e infecciones respiratorias de vías altas
CN111184749B (zh) * 2020-02-17 2023-10-03 上海城建职业学院 一种益生菌菌剂、棉签及其制备方法和应用
WO2021216869A1 (en) * 2020-04-24 2021-10-28 Joseph Scivoletto Nasal spray composition
AU2022420738A1 (en) * 2021-12-20 2024-05-30 Société des Produits Nestlé S.A. Secretory iga-biotic complexes and uses thereof
WO2023209224A1 (en) 2022-04-29 2023-11-02 Université Libre de Bruxelles Probiotics for the prevention or treatment of viral respiratory infections

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
JPS62138147A (ja) * 1985-12-12 1987-06-20 Snow Brand Milk Prod Co Ltd ガラクトオリゴ糖類配合飼料
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
CN1200701C (zh) 1997-02-21 2005-05-11 艾博特公司 降低坏死性小肠结肠炎发生率的组合物
CN1208620A (zh) * 1997-08-15 1999-02-24 陈秀枢 一种含双歧杆菌和乳杆菌的组合物
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CN1330542A (zh) 1998-12-15 2002-01-09 美国家用产品公司 对肠道完整性有维持和修复作用的方法与组合物
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AU4905300A (en) * 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
FI113741B (fi) 1999-11-01 2004-06-15 Valio Oy Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
AU2001233529A1 (en) * 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
JP2003535903A (ja) 2000-06-19 2003-12-02 ミューコプロテック・プロプライエタリー・リミテッド プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
KR100845456B1 (ko) * 2001-02-06 2008-07-10 소시에떼 데 프로듀이 네슬레 소시에떼아노님 젖산균 및 비피도균에 의한 내독소 결합
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP3853673B2 (ja) 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
EP1243273A1 (en) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
EP1260227A1 (en) * 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
US20040265291A1 (en) 2003-01-24 2004-12-30 Flora Technology Inc. Compositions and methods for restoring bacterial flora
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
CN1183960C (zh) * 2003-02-27 2005-01-12 四川大学 双歧杆菌细胞壁蛋白在制药中的应用
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies

Also Published As

Publication number Publication date
EP1768681A1 (en) 2007-04-04
WO2006007526A1 (en) 2006-01-19
TWI374745B (en) 2012-10-21
TW200612971A (en) 2006-05-01
MXPA06014555A (es) 2007-03-23
CN101014351A (zh) 2007-08-08
NO341408B1 (no) 2017-10-30
RU2332224C1 (ru) 2008-08-27
US7862808B2 (en) 2011-01-04
KR20070052246A (ko) 2007-05-21
CN101014351B (zh) 2011-08-24
CA2570481C (en) 2014-09-09
CA2570481A1 (en) 2006-01-19
HK1111883A1 (en) 2008-08-22
MY145410A (en) 2012-02-15
US20060018890A1 (en) 2006-01-26
NO20072906L (no) 2007-06-07

Similar Documents

Publication Publication Date Title
BRPI0512584A (pt) método para prevenir ou tratar infecções respiratórias e otite média em lactentes
WO2006050489A3 (en) Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
MY157860A (en) Prevention and treatment of secondary infections following viral infection
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
TW200633995A (en) Andrographolide derivatives to treat viral infections
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
HK1124546A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2018097628A3 (ko) 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
WO2008090287A3 (fr) Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida
BR112012005837A8 (pt) Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.
MY160406A (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
BRPI0608328A2 (pt) uso de lactobacillus rhamnosus gg para tratamento, prevenção ou redução de inflamação sistêmica em um bebê alimentado com fórmula
BRPI0503827A (pt) métodos para prevenir ou tratar infecções respiratórias em lactentes
WO2006096769A3 (en) Use of alpha-glucosidase inhibitors to treat alphavirus infections
WO2007035879A3 (en) Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
ATE458748T1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
WO2010138419A3 (en) Materials and methods for treating viral infections
BR112014014805A2 (pt) processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
MX2022012576A (es) Inhibidores de axl para terapia antiviral.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MEAD JOHNSON NUTRITION COMPANY (US)

Free format text: TRANSFERIDO DE: BRISTOL-MYERS SQUIBB COMPANY

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: MJN U.S. HOLDINGS LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]